. 2023 Sep 19;13(9):e12297. doi: 10.1002/clt2.12297

TABLE 3.

Recommended first‐line treatments for patients with HAE. ¹⁷

Indication	First‐line adolescents ≥12 years/adults	First‐line pediatrics (<12 years)
Acute/on demand	pdC1‐INH (IV)	pdC1‐INH (IV)
	rhC1‐INH (IV)	rhC1‐INH (IV) ^a
	Ecallantide (SC)	Icatibant (SC) ^a
	Icatibant (SC)
Short‐term prophylaxis	pdC1‐INH (IV)	pdC1‐INH (IV) ^a
Long‐term prophylaxis	pdC1‐INH (IV/SC)	pdC1‐INH (IV) ^b
	Lanadelumab	Tranexamic acid ^c
	Berotralstat

Note: Availability and indications of treatments vary between countries.

Abbreviations: HAE, hereditary angioedema; IV, intravenous; pdC1‐INH, plasma‐derived C1‐esterase inhibitor; rhC1‐INH, recombinant human C1‐esterase inhibitor; SC, subcutaneous.

^{^a}

≥2 years.

^{^b}

≥6 years.

^{^c}

When C1‐INH is not available.